Search results
Big Pharma Teva Accused of Delaying Generic Drug Competition | Connecticut Law Tribune
Law.com· 2 days agoLawsuits against large pharmaceutical companies alleging the use of inaccurate patent listings to...
Pay for Delay is Sometimes Okay
The National Law Review· 16 hours agoThe US Court of Appeals for the Second Circuit affirmed the dismissal of a lawsuit against pharmaceutical companies accused of violating antitrust laws...
Hims & Hers will sell knock-off Ozempic for $199 — and it won’t be approved by FDA
NY Post via Yahoo Finance· 12 hours agoCompounding medications are commonly used when a patient is allergic to an ingredient in a...
Hims debuts $199 weight-loss shots at 85% discount to Wegovy
Detroit News· 4 days agoIn just a few years, Hims & Hers Health Inc. reached almost $1 billion in sales by making it easy to...
How Drug Companies Stifle Competition With ‘Product Hopping’
Forbes· 3 days agoActavis had spent that sum to acquire Forest and its portfolio of pharmaceutical products. Forest...
This Unpopular Dividend Stock Is a Buy
Motley Fool via Yahoo Finance· 21 hours agoBMS is dealing with the loss of patent protection for its cancer medication...categories sport failure rates over 90%. BMS has successfully lowered its...
Viatris Inc's Dividend Analysis
GuruFocus.com via Yahoo Finance· 2 days agoViatris Inc (NASDAQ:VTRS) recently announced a dividend of $0.12 per share, payable on 2024-06-14, with the ex-dividend date set for 2024-05-23. As...
Guest opinion: Don't break the life-sciences industry - San Francisco Business Times
The Business Journals· 13 hours agoThe last discovery of a new class of antimicrobials that reached the market was in 1987. If...
McKesson (MCK) Hits 52-Week High: What's Driving the Stock?
Zacks via Yahoo Finance· 3 days agoStiff Competition: Distribution...wholesalers, service merchandisers, self-warehousing chains,...
Cipla receives final approval for the generic version of Somatuline® Depot (Lanreotide) Injection...
The Woonsocket Call· 2 days agoCipla's Lanreotide Injection is AP-rated therapeutic equivalent generic version of Somatuline® Depot (Lanreotide) Injection.
